Actualités sur Health

30.06.2014 – 10:03
Bristol-Myers Squibb GmbH & Co. KGaA
SHE Day: The Strong, HIV Positive, Empowered Women (SHE) Faculty and Bristol-Myers Squibb Celebrated Four Years of SHE, a First-of-Its Kind Programme Addressing the Specific Challenges Faced by Women Living with HIV in Europe
Paris (ots/PRNewswire) - - The SHE network continues to expand across Europe to empower and educate women living with HIV and their health care providers - More than 60 SHE units, multidisciplinary teams based in HIV clinics and dedicated to women with HIV, have been implemented in 18 countries 'SHE' (Strong, HIV ...
plus
30.06.2014 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives US$248 Million Cash Refund From the Canadian Revenue Authorities, Expects a Further US$162 Million in Late 2014
Dublin (ots/PRNewswire) - Shire plc ("Shire" or the "Company") announces that its Canadian subsidiary(1) has received assessments from the Canadian revenue authorities, entitling it to total cash refunds equivalent to US$410 million(2). Following receipt of the assessments(3), the Company has recorded a net credit ...
plus
26.06.2014 – 15:17
UBM Live
CPhI Istanbul Cements Rapid Pharma Sector Growth in Eurasia, Central Asia and MENA Regions
Istanbul (ots/PRNewswire) - Successful first edition facilitates international partnerships and continued domestic manufacturing growth Leading events organiser, UBM Live, announces the successful launch of CPhI Istanbul 2014 [http://www.cphi-istanbul.com ], which took place on June 4th-6th 2014 at the Lutfi Kirdar International Convention and Exhibition Centre in ...
plus
25.06.2014 – 17:49
Shire Pharmaceuticals Group Plc
Shire Comments on AbbVie's Unchanged Proposal
Dublin, Ireland (ots/PRNewswire) - NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Shire plc ("Shire" or the "Company") notes today's announcement by AbbVie Inc. ("AbbVie") repeating its proposal of May 30, 2014, which comprised GBP20.44 in cash and 0.7988 AbbVie shares per Shire ...
plus
24.06.2014 – 13:02
Janssen Pharmaceutica
Fighting for Their Lives: Economist Intelligence Unit Report Finds Patient Groups Lead Global Efforts to Address Hepatitis C
Beerse, Belgium (ots/PRNewswire) - New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide 'Tackling hepatitis C: Moving towards an integrated policy approach', a report published by The Economist Intelligence Unit (EIU) today reveals that many ...
plus
18.06.2014 – 14:32
Janssen Pharmaceutica
Janssen Announces License Agreement With Vertex to Develop Novel Treatment for Influenza A
Titusville, New Jersey (ots/PRNewswire) - Janssen Pharmaceuticals, Inc. (Janssen) announced today that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787, a novel medicine in Phase II development for the treatment of influenza A. VX-787 is an investigational ...
plus

16.06.2014 – 18:06
Sanofi Diabetes
TEENs Study Shows Achieving Target Blood Sugar Levels is Associated with Better Quality of Life for Young People with Type 1 Diabetes
Paris (ots/PRNewswire) - - Findings set foundation to drive recommendations for enhancing care - Sanofi announced today the first results of the TEENs Registry Study, the largest contemporary real-world study of the care of nearly 6,000 young people with type 1 diabetes, ages 8 to 25. The findings not only ...
plus
16.06.2014 – 12:12
UBM Live
Fi Asia-China to Welcome the Global Food Industry to Shanghai this Month
Amsterdam (ots/PRNewswire) - - China's most important gathering of food and beverage industry professionals China's leading nutritional ingredients event, Food ingredients (Fi) Asia China, Health ingredients (Hi) and Natural ingredients (Ni), will take place this month, June 26-28 2014 in Shanghai, China. This is the premier event in China offering food & beverage ...
plus
14.06.2014 – 19:34
Sanofi Diabetes
Sanofi's Lyxumia® (lixisenatide) Showed More Pronounced After-Test-Meal Blood Sugar Lowering Than Liraglutide When Both Were Added to Insulin Glargine
Paris (ots/PRNewswire) - Sanofi announced today that Lyxumia(R) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when ...
plus
14.06.2014 – 19:07
Sanofi Diabetes
Sanofi Announces Positive Phase 3 Results for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) in Japanese People with Uncontrolled Diabetes
Paris (ots/PRNewswire) - - In EDITION JP I and II, investigational Toujeo(R)demonstrated similar blood sugar control with fewer night-time low blood sugar events over 6-month study period, vs. Lantus(R)- Sanofi announced today full results from EDITION JP I and EDITION JP II that showed Toujeo(R) (insulin glargine ...
plus
12.06.2014 – 12:02
Janssen R&D Ireland Ltd
Janssen Collaborates With ViiV Healthcare to Develop Two-Drug Single Tablet Regimen for the Maintenance Treatment of People Living With HIV
Cork, Ireland (ots/PRNewswire) - Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT(R)) and ViiV's ...
plus
10.06.2014 – 20:17
Sanofi Diabetes
Sanofi to Present New Clinical Data at American Diabetes Association 74th Scientific Sessions
Paris, France (ots/PRNewswire) - - New results for Toujeo(R)(insulin glargine [rDNA origin] injection, 300 U/mL; "U300") from EDITION I/II/III meta-analysis, EDITION III, IV, JP 1 and JP 2 studies are among over 65 abstracts to be presented - Sanofi announced today that new data on U300, Lyxumia(R) (lixisenatide) ...
plus

10.06.2014 – 13:53
Merck Healthcare
Merck Serono Announces FDA Clearance for Auxogyn's Early Embryo Viability Assessment (Eeva®) System
Darmstadt, Germany (ots/PRNewswire) - - FDA clearance validates Eeva System, which enables in-vitro fertilization (IVF) clinicians to offer the proprietary Eeva Test and further demonstrates commitment by Merck Serono and Auxogyn to bring innovative technologies to the IVF community - Eeva Test first-of-a-kind ...
plus
09.06.2014 – 15:02
ALK
ALK Presents Phase III Data on House Dust Mite SLIT-tablet at EAACI Annual Congress in Copenhagen
Hørsholm, Denmark (ots/PRNewswire) - First sublingual allergy immunotherapy tablet with robust results in allergic rhinitis and allergic asthma. Data supports European regulatory filing in 2H 2014 Today, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has presented key trial results on its new sublingual allergy ...
plus
08.06.2014 – 19:01
ALK
Allergy Experts Address Pivotal Questions in Treatment of Grass Pollen Allergy Sufferers
Copenhagen, Denmark (ots/PRNewswire) - And highlight a decade of clinical evidence demonstrating long-term efficacy and tolerability of once-daily GRAZAX(R) SLIT-tablet at EAACI 2014 A group of eminent allergy and respiratory professors presented data specifically addressing numerous key questions within the allergy community concerning grass SLIT-tablets, with ...
plus
01.06.2014 – 01:31
Merck Healthcare Germany
Merck to Collaborate with Sysmex Inostics on a Blood-Based RAS Biomarker Test
Darmstadt, Germany (ots/PRNewswire) - - Development and commercialization agreement on blood-based RAS biomarker mutation status test for (metastatic) colorectal cancer (mCRC) - This non-invasive, fast and easy-to-perform diagnostic test is expected to provide a real-time reflection of a patient's RAS mutation status to help guide clinical decision making in mCRC Merck ...
plus
31.05.2014 – 15:06
AstraZeneca GmbH
Investigational Drug AZD9291 Shows Clinical Responses in Patients With Advanced NSCLC Who Have Previously Failed on Established EGFR TKIs
Chicago (ots/PRNewswire) - Data from the ongoing Phase I AURA study in patients with epidermal growth factor receptor mutation positive (EGFRm+), advanced non-small cell lung cancer (NSCLC), demonstrate that the overall disease control rate was 94 percent for patients with EGFR T790M+ tumours - meaning that their ...
plus
31.05.2014 – 13:33
Janssen Pharmaceutica
Ibrutinib Three Year Follow-up of Single-Agent and Combination Study Results in Chronic Lymphocytic Leukemia
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Oral presentation (Abstract 7014) and poster session (Abstract 7009) featured at the 50th annual meeting of the American Society of Clinical Oncology Three year follow-up data from the Phase 1b/2 PCYC-1102 trial of monotherapy ibrutinib showed continued ...
plus

31.05.2014 – 13:32
Janssen Pharmaceutica
Ibrutinib RESONATE(TM) Data Show Significant Improvements in Progression-Free Survival and Overall Survival in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Beerse, Belgium (ots/PRNewswire) - /NOT INTENDED FOR UK MEDIA/ Phase 3 data (Abstract LBA7008) featured in the official press programme of the 50th annual meeting of the American Society of Clinical Oncology and simultaneously published in The New England Journal of Medicine Data from the international, multicentre ...
plus
29.05.2014 – 08:31
Merck Healthcare
Merck Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage Investigational Compounds in Difficult-to-Treat Cancers
Darmstadt, Germany (ots/PRNewswire) - ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine Merck ...
plus
27.05.2014 – 14:17
Takeda Pharmaceutical Company Limited
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn's Disease
Zurich And Osaka, Japan (ots/PRNewswire) - Discovery Minerals (DSCR) Undervalued and Nearing Its SqueezeTrigger Price According to WealthMakers.com Report May 27, 2014 WEALTHMAKERS.COM / www.wealthmakers.com [http://www.wealthmakers.com ] , a Wall Street research and trading firm providing unbiased statistical stock ...
plus
26.05.2014 – 08:31
Merck Healthcare
Merck Serono Supports 6th International Thyroid Awareness Week
Darmstadt, Germany (ots/PRNewswire) - - For the 6th time in a row Merck Serono takes part in the International Thyroid Awareness Week with focus on HIGH FIVE - Five reasons to be aware of thyroid disease: Thyroid cancer, autoimmunity, infertility, anxiety/depression, and iodine deficiency Merck Serono, the biopharmaceutical division of Merck, together with Thyroid ...
plus
23.05.2014 – 12:56
Janssen Pharmaceutica
Janssen to Exhibit Expanding Portfolio of Research at 2014 European Hematology Association (EHA) Annual Meeting
Beerse, Belgium (ots/PRNewswire) - - Research in haematological malignancies features VELCADE(R), siltuximab, ibrutinib and daratumumab - Note: This release corresponds to EHA abstracts S1345, P958, P957, P369, P353, P960, P1211, P1209, P461, P356, P350, P434, P109 Janssen Pharmaceutica NV announced data related to ...
plus
19.05.2014 – 09:03
UBM Live
All for One and One for All
London (ots/PRNewswire) - Health and safety bodies unite to launch Health & Safety Week 2014 To celebrate the UK's 85% reduction in fatal accidents since the introduction of the Health and Safety at Work Act in 1974, the country's leading health and safety bodies are uniting to launch Health & Safety Week 2014, 16th - 20th June, at Safety & Health Expo and reinstate a positive image for this exceptionally worthwhile profession. (Logo: ...
plus

16.05.2014 – 10:27
Pharma IQ
Industry Interview from Pharma IQ's 4th Annual Packaging and Labelling Forum Resource Centre: Can a Label Change Your Patient's Behaviour?
London (ots/PRNewswire) - Is it really possible to develop labelling that is legally compliant, commercially viable, and influence a patient's behaviour? Pharma IQ recently worked with Dr. Karel van der Waarde, to review this question. The following article is the result - it addresses the recent falsification and ...
plus
15.05.2014 – 10:53
Merck Healthcare Germany
Merck Announces New Retrospective Analysis Shows Significant Clinical Benefit in Overall Survival for Metastatic Colorectal Cancer Patients with RAS Wild-Type Tumors Receiving Erbitux plus FOLFIRI
Darmstadt, Germany (ots/PRNewswire) - ASCO Abstract Number: 3506 - In a retrospective analysis of the Phase III CRYSTAL* study, which assessed RAS tumor status, significant clinical benefit was observed in mCRC patients with RAS wild-type tumors receiving Erbitux plus FOLFIRI, compared with FOLFIRI alone - No ...
plus
14.05.2014 – 13:00
IRC
$300,000 Grant to be Awarded to Winning Proposal on "Neurodegeneration: Perceptual Consequences and Quantification in Human Subjects" / The Hearing Industry Research Consortium (IRC) issues 2014 Grant
Singapore (ots) - Since 2012 the hearing industry's largest manufacturers have collaborated to sponsor a non-competitive, mutually agreed upon research agenda benefitting the hearing aid industry, its customers, and end users. The framework for this collaboration is the Hearing Industry Research Consortium (IRC). ...
plus
13.05.2014 – 12:30
UBM Live
CPhI South East Asia Driving Fastest Growing ASEAN Economy
Amsterdam (ots/PRNewswire) - Indonesian pharmaceutical market to grow 6% annually Leading events organiser, UBM Live, announces the return of CPhI South East Asia. Now in its third consecutive year, the leading pharmaceutical ingredients event, co-located with P-MEC and InnoPack, will take place at the Jakarta International Expo, Indonesia from 20th to 22nd May 2014. (Logo: ...
plus
12.05.2014 – 13:02
Shire plc and Lumena Pharmaceuticals
Shire Adds to Rare Disease Portfolio with Acquisition of Lumena Pharmaceuticals, Bringing Late Stage Compounds for Rare GI/Hepatic Conditions
Dublin And San Diego (ots/PRNewswire) - - Acquisition of Lumena Pharmaceuticals, a biopharmaceutical company with late stage rare disease pipeline assets - Adds to Shire's rare diseases portfolio and leverages this expertise, and is a perfect combination with Shire's already strong Gastrointestinal (GI) presence - ...
plus
12.05.2014 – 11:55
Novo Nordisk
NovoEight® provides long-term reduction of bleeding in people with haemophilia A
Copenhagen, Denmark (ots/PRNewswire) - For healthcare media only, not for US, UK or Spanish journalists Today, Novo Nordisk announced new phase 3 interim data from its guardian(TM)2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight(R) (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term ...
plus

Précédent44454647484950515253Suivant